Adenosine Kinase Inhibitor (hydrate)

Adenosine provides homeostatic reductions in cell excitability during tissue stress and trauma by negatively modulating intercellular signaling. Adenosine kinase is the key metabolizing enzyme that regulates cellular adenosine concentrations. Inhibition of adenosine kinase represents a mechanism to selectively enhance the protective actions of adenosine during tissue trauma without producing the nonspecific effects associated with the systemic administration of adenosine receptor agonists. Adenosine kinase inhibitor is a non-nucleoside pyridopyrimidine compound that blocks the action of adenosine kinase in an adenosine-competitive and reversible manner (IC₅₀ = 1.7 nM in cell-free assays).¹ It is several orders of magnitude more selective for adenosine kinase over the adenosine A₁, A_2A, A₃ receptors, the adenosine transporter, and adenosine deaminase.¹ This compound has been shown to suppress nociception in various rodent pain models.^1,2

WARNING This product is not for human or veterinary use.

1. Jarvis, M.F., Yu, H., Kohlhaas, K., et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J. Pharmacol. Exp. Ther. 295(3), 1156-1164 (2000).

2. Kowaluk, E.A., Mikusa, J., Wismer, C.T., et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J. Pharmacol. Exp. Ther. 295(3), 1165-1174 (2000).